Queens University Belfast – Confidence in Concept 2019

Lead Research Organisation: Queen's University Belfast
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
 
Description CLEC3B - a novel biomarker for heart failure: cohort evaluation and development of a point of care prototype
Amount £85,525 (GBP)
Funding ID NICHS - 2022_H01 - CLEC3B 
Organisation Northern Ireland Chest Heart and Stroke Association (NICHS) 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2023 
End 05/2024
 
Description Cathepsin S inhibition as a treatment for lung inflammation and lung damage in Chronic Lung Disease
Amount £707,077 (GBP)
Funding ID MR/X001504/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2023 
End 01/2026
 
Description Development of vaccine to prevent Pseudomonas aeruginosa infection - North-South Research Programme 2021
Amount £3,000,000 (GBP)
Funding ID HEA North South 2021 - Strand II - AVIRT via UCD 
Organisation Higher Education Authority 
Sector Public
Country Ireland
Start 02/2022 
End 01/2026
 
Description Developmental Pathway Gap Fund (DPGF)
Amount £226,068 (GBP)
Funding ID MR/Y503447/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2024 
End 09/2025
 
Description NXW 23 ICURe Discover: 'Development of Multi-Drug Sutures using Deep Eutectic Reactive Technology for the Prevention of Surgical Site Infections'
Amount £3,500 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2023 
End 06/2023
 
Description Opportunity Led Research: InflaTMP: Design of a novel combination anti-inflammatory and anti-viral biotherapeutic for COVID-19 targeting the NLRP3 inflammasome and TMPRSS2
Amount £143,000 (GBP)
Funding ID HSC R&D COM/5627/20 
Organisation Health and Social Care in Northern Ireland (HSCNI) 
Sector Public
Country United Kingdom
Start 03/2021 
End 03/2022
 
Description Opportunity-Led Professor Ultan Power - Repurposing FDA-approved drugs for treatment of 2019-nCoV-induced disease_x000D_
Amount £208,070 (GBP)
Funding ID COM/5613/20 
Organisation Public Health Agency (PHA) 
Sector Public
Country United Kingdom
Start 09/2020 
End 09/2021
 
Description Repurposing approved drugs as potent antiviral combinations to treat COVID-19 disease.
Amount £640,433 (GBP)
Funding ID MRC - BMC DPFS - MR/W021641/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2022 
End 12/2024
 
Description Research Development: NI COVID-19 Antibody Development Alliance
Amount £265,500 (GBP)
Funding ID INI - RD05201431 - NI Covid-19 Antibody Development Alliance 
Organisation Invest Northern Ireland 
Sector Public
Country United Kingdom
Start 06/2020 
End 12/2021
 
Description Science Foundation Ireland (SFI) SDG Challenge: BIOTOPE 2 - Prize Phase
Amount € 699,869 (EUR)
Organisation Science Foundation Ireland (SFI) 
Sector Charity/Non Profit
Country Ireland
Start 11/2023 
End 10/2025
 
Description Science Foundation Ireland (SFI) SDG Challenge: BIOTOPE 2 - Seed and Concept Phase
Amount € 388,739 (EUR)
Organisation Science Foundation Ireland (SFI) 
Sector Charity/Non Profit
Country Ireland
Start 06/2022 
End 06/2024
 
Description Targeting Deubiquitinases to Treat Drug-Resistant Colorectal Cancer
Amount £225,656 (GBP)
Funding ID 56232 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 02/2021 
End 12/2023
 
Title ANTI VIRAL THERAPY 
Description The invention relates to novel compounds of formula (1), or pharmaceutically acceptable salts thereof, for use in treatment of viral infection. The invention further relates to methods of treating viral infection by administering a therapeutically effective amount of the compound of formula (1). 
IP Reference WO2022195296 
Protection Patent / Patent application
Year Protection Granted 2022
Licensed No
Impact Nothing as yet
 
Title SUTURES 
Description The invention relates to a suture thread material comprising at least one polymer and at least one eutectic mixture. The polymer can be a biocompatible polymer such as polycaprolactone or PLGA. The eutectic mixture may comprise maleic acid and an antibiotic such as metronidazole. Other eutectic mixtures can be used in suture thread materials to reduce SSis and/or to decrease pain and/or to increase lubricity of sutures. The invention also provides a method for the production of sutures with drug loadings, the method comprising the use of therapeutic deep eutectic solvent (THEDES) technology to significantly increase drug content in suture matrices. 
IP Reference WO2022194900 
Protection Patent / Patent application
Year Protection Granted 2022
Licensed No
Impact Discussions around licensing